

**Kanabo Group Plc**  
("Kanabo" or the "Company")

**Board Changes**

Kanabo Group plc (LSE: KNB), a health tech company with digital health services and specialist medicines, announces that **Mr David Tsur** will be stepping down from the Board of Directors with effect from **30 January 2025**. Mr Tsur has served as a member of the Board since Admission in early 2021 and held the position of Chairman for more than 2 years. He has been part of the Kanabo journey since 2018.

**Avihu Tamir, CEO of Kanabo**, commented:

"David has personally mentored me since the earliest days of Kanabo and has been integral to some of our most significant achievements. His wealth of experience, unwavering support, and commitment to our mission have been invaluable not only to the Company but also to my own journey. I extend my gratitude to David for everything he has done for Kanabo, and I wish him the very best."

**Mr Ian Mattioli, Chairman of the Board of Directors**, said:

"On behalf of the entire Board, I would like to express our sincere gratitude to David for his contributions to Kanabo. He has served the Company professionally and committedly, and we are grateful for his invaluable insights and guidance. We wish him all the best as he embarks on new opportunities."

Kanabo further announces its intention to appoint a **new UK-based** Director to the Board. A separate announcement will be made in due course.

**Enquiries:**

**Kanabo Group plc**

Avihu Tamir, Chief Executive Officer

Ian Mattioli, Non-Executive Chair of the Board

**Peterhouse Capital Ltd (Financial Adviser)**

+44 (0)20 7469 0930

Guy Miller / Lucy Williams / Charles Goodfellow

**About Kanabo Group plc**

Kanabo Group plc (LSE: KNB) is a digital health company committed to transforming patient care through its innovative technology platform and specialised treatment offerings. Since its inception in 2017, Kanabo has been focused on researching, developing, and commercialising regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.

Kanabo's NHS-approved online telehealth platform, The GP Service, provides patients with video consultations, online prescriptions, and primary care services. Leveraging its telehealth capabilities, in February 2023, Kanabo launched Treat-It, an online clinic focused on chronic pain management that provides patients with secondary care. In June 2024, the Treat-It partnership was expanded to 14 other in-pharmacy locations.

With its two complementary business divisions, Kanabo has established itself as an end-to-end digital health provider. It offers telehealth consultations, prescriptions and tailor-made treatments.

The Company's partially owned subsidiary, Kanabo Agritec Ltd, is a cultivation consultancy supporting cannabis businesses in developing new farms through infrastructural, research, and product guidance. These farms deliver high-quality raw materials for Kanabo's formulas and

product line.

At Kanabo Group Plc, we are dedicated to providing patients with the highest quality medical treatments and more accessible healthcare experiences.

**Visit [www.kanabogroup.com](http://www.kanabogroup.com) for more information.**

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAFLFIDLAIIVII